FLINT, Mich. — Paul Urick has been promoted to senior vice president of industry relations for pharmaceutical account management and payer strategies at Diplomat Pharmacy Inc. In his expanded role, Urick will now drive efforts in payer strategies through the development of specialty initiatives to reduce costs through patient-centered care, while also continuing to lead
Diplomat Pharmacy has gone live with what the company describes as a “re-envisioned” website. The nation’s largest independent specialty pharmacy said its revamped website is “user-centric, story-driven, knowledge-based and mobile-friendly.” Key features include a sleek, intuitive layout; fresh, relevant content such as Diplomat’s “Areas of Excellence”; guided user experiences for patients, prescribers and caregivers; and
FLINT, Mich. — Gary Kadlec, president of specialty pharmacy Diplomat Pharmacy Inc., has been elected as board chairman for the American Foundation for Pharmaceutical Education (AFPE). An independent foundation, the AFPE supports U.S. pharmaceutical education, including graduate education, training and research in such disciplines as clinical pharmaceutical science, medicinal/pharmaceutical chemistry, pharmacology/toxicology, pharmaceutics, pharmacoeconomics, pharmacognosy, pharmacokinetics/metabolism,
FLINT, Mich. — Diplomat Pharmacy Inc. has been awarded full Specialty Pharmacy reaccreditation by URAC, a Washington, D.C.-based health care accrediting organization that establishes quality standards for the health care industry. Diplomat has been fully accredited for specialty pharmacy since 2012. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care
MADISON, Wis. — Restore Health announced this month it has entered into an agreement to acquire the compounding pharmacy assets of Diplomat Pharmacy Inc. Financial terms of the agreement weren’t disclosed. Restore Health said the deal bolsters its compounding pharmacy and personalized medicine business and enables Diplomat to sharpen its focus on its core specialty
MADISON, Wis. — Personalized medicine solution provider Restore Health plans to acquire the compounding pharmacy assets of Diplomat Pharmacy Inc. Financial terms of the agreement weren’t disclosed. Restore Health said Thursday that the deal bolsters its compounding pharmacy and personalized medicine business and enables Diplomat to sharpen its focus on its core specialty pharmacy operations.
Describing itself as the nation’s largest independent specialty pharmacy, Diplomat Pharmacy Inc. serves patients and physicians in all 50 states and offers medication management programs for complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. The specialty pharmacy provider has made the most of
FLINT, Mich. — Diplomat Pharmacy Inc. is a growing company in a quickly growing industry. The specialty pharmacy provider has made the most of its independence, says chairman and chief executive officer Phil Hagerman, and continues to do so after last year’s initial public offering. Even though Diplomat has become publicly traded, “we absolutely still
FLINT, Mich. — Diplomat Pharmacy Inc. has acquired Burman’s Specialty Pharmacy in an $82.8 million deal. Burman’s, based in Pennsylvania, is a provider of individualized patient care with a primary focus on hepatitis C. “Burman’s shares our strong commitment to patient care,” said Diplomat chairman and chief executive officer Phil Hagerman. “We acquired Burman’s to
FLINT, Mich. — Diplomat Pharmacy Inc. has purchased Burman’s Specialty Pharmacy in a deal valued at more than $82 million. Diplomat said Friday that Burman’s, located in the greater Philadelphia area, is a provider of individualized patient care with a primary focus on hepatitis C. For the 12 months ended May 31, Burman’s generated about
FLINT, Mich. — Diplomat Pharmacy Inc. has begun a follow-on public offering of 7.4 million shares of its common stock. The independent specialty pharmacy said late Monday that it’s selling 4.4 million shares of common stock, and certain shareholders are selling 3 million shares of common stock. In addition, the company and selling shareholders aim
FLINT, Mich. — Diplomat Pharmacy Inc. has filed a registration statement with the Securities and Exchange Commission for a follow-on public offering of its common stock. The independent specialty pharmacy, the nation’s largest, said late Friday that the offering could raise about $200 million, depending on market conditions. Last October, Diplomat completed an initial public
FLINT, Mich. — Diplomat Pharmacy, which posted strong financial results for fiscal 2014, is acquiring BioRx LLC, a specialized pharmacy and infusion services company. Based in Cincinnati, BioRx provides treatments for patients with ultra-orphan and rare, chronic diseases. Terms of the agreement call for Diplomat to buy BioRx for $210 million in cash and $105
